XOMA Royalty (XOMA) Enterprise Value (2010 - 2026)
XOMA Royalty (XOMA) reported Enterprise Value of -$66.1 million for Q1 2026, up 28.68% on a YoY basis from -$51.3 million in Q1 2025, and down 4.4% sequentially from -$63.3 million in Q4 2025.
XOMA Royalty (XOMA) Enterprise Value (2010 - 2026) Analysis & Trends
XOMA Royalty (XOMA) has 17 years of Enterprise Value data on file, last reported at -$66.1 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value rose 28.68% year-over-year to -$66.1 million; the trailing twelve-month figure through Mar 2026 stood at -$66.1 million (up 28.68% YoY), and the FY2025 full-year result was -$63.3 million, up 23.72% from the prior year.
- Enterprise Value fell to -$66.1 million in Q1 2026, from -$63.3 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of $12.9 million in Q2 2025 to a low of -$153.4 million in Q4 2023.
- A 5-year average of -$70.6 million and a median of -$78.7 million in 2022 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value plunged 45705.97% in 2023 and soared 108.95% in 2025, its largest moves.
- Tracing XOMA's Enterprise Value over 5 years: stood at -$335000.0 in 2022, then sank by 45705.97% to -$153.4 million in 2023, then surged by 45.93% to -$83.0 million in 2024, then grew by 23.72% to -$63.3 million in 2025, then retreated by 4.4% to -$66.1 million in 2026.
- Business Quant data shows XOMA's Enterprise Value at -$66.1 million in Q1 2026, -$63.3 million in Q4 2025, and -$108.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - | -66.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -66.08 Mn |
| Dec 31, 2025 | -63.29 Mn |
| Sep 17, 2025 | -108.00 Mn |
| Jun 30, 2025 | 12.95 Mn |
| Mar 31, 2025 | -92.65 Mn |
| Dec 31, 2024 | -82.97 Mn |
| Sep 30, 2024 | -4.80 Mn |
| Jun 30, 2024 | -144.60 Mn |
| Mar 31, 2024 | -136.40 Mn |
| Dec 31, 2023 | -153.45 Mn |
| Sep 30, 2023 | -33.69 Mn |
| Jun 30, 2023 | -31.77 Mn |
| Mar 31, 2023 | -44.61 Mn |
| Dec 31, 2022 | -335,000.00 |
| Sep 30, 2022 | -78.73 Mn |
| Jun 30, 2022 | -83.71 Mn |
| Mar 31, 2022 | -88.34 Mn |
| Dec 31, 2021 | -95.38 Mn |
| Sep 30, 2021 | -72.17 Mn |
| Jun 30, 2021 | -81.26 Mn |